Celadon Pharmaceuticals Secures £30k Series C+ Funding at £300m Valuation

London-based Celadon Pharmaceuticals Limited has completed a £30k Series C+ funding round, achieving an estimated post-money valuation of £300m. The allotment, filed on 17 February 2026 following an initial transaction date of 27 January 2026, represents a minor equity injection for the late-stage pharmaceutical manufacturer.

Founded in August 2018 shortly after the UK legalised cannabis for medicinal purposes, Celadon Pharmaceuticals researches, cultivates,